U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06943833) titled 'A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)' on March 11.
Brief Summary: This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT).
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Locally Advanced Cervical Cancer
Intervention:
BIOLOGICAL: Volrustomig
IV infusion
Recruitment Status: RECRUITING
Sponsor: AstraZeneca
Disclaimer: Curated by HT Syndication....